Scott E Brodie, MD, PhD
Dr. Scott Brodie is a Professor of Ophthalmology specializing in Medical Retina and Clinical Electrophysiology, and since 1985 has been the Director of the Department's Clinical Electrophysiology Laboratory. With expansive backgrounds in mathematics, biophysics, and genetics, he brings a unique perspective to the study of inherited, metabolic, and degenerative diseases of the retina in his clinical practice and research. He has developed and directs a comprehensive state-of-the-art clinical and research electrophysiologic laboratory, which provides the co mplete range of physiologic testing of visual fuction, including
· Full-field (“Ganzfeld) Electroretinography (ERG)
· Patern ERG
· Multifocal ERG
· Visual Evoked Potentials (VEP)
· Color-vision testing (including Ishihara, HRR, Farnsworth D-15, Desaturated 15 Hue, F-M 100 Hue, and Nagel Anomaloscope)
· Dark Adaptometry
The full spectrum of standard clinical tests, including contrast sensitivity, Humphrey and Goldmann visual fields, fundus photography, spectral-mode optical coherence tomography (OCT), and fundus autofluorescence imaging are also available.
Dr. Brodie received his B.A. Summa Cum Laude and an M.A. in Mathematics from Wesleyan University. He received his Ph.D. in biophysics from The Rockefeller University and his M.D. from Cornell University Medical College. After his residency at The New York Hospital, he received his fellowship in medical retina at New York University Medical Center where he held the John Kluge Fellowship from the National Retinitis Pigmentosa Foundation. Dr. Brodie is a Diplomate of the American Board of Ophthalmology.
Dr. Brodie has published over 75 medical and scientific, primarily in the study of the retina from the molecular level, genetics, neurologic, and psychophysical models, electrophysiologic testing for early diagnosis of glaucoma, and early identification of retinopathy in AIDS. He has taken a special interest in several rare diseases, including Epidermolysis Bullosa, Fabry Disease, Niemann-Pick Disease, and, in collaboration with the Ocular Oncology Service at Memorial Sloan-Kettering Cancer Center, Retinoblastoma.